|
1
|
Amir J, Metzker A, Krikler R and Reisner
SH: Strawberry hemangioma in preterm infants. Pediatr Dermatol.
3:331–332. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bryan BA, Dennstedt E, Mitchell DC, Walshe
TE, Noma K, Loureiro R, Saint-Geniez M, Campaigniac JP, Liao JK and
D'Amore PA: RhoA/ROCK signaling is essential for multiple aspects
of VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hogeling M, Adams S and Wargon O: A
randomized controlled trial of propranolol for infantile
hemangiomas. Pediatrics. 128:e259–e266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sans V, de la Roque ED, Berge J, Grenier
N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine
K, Vergnes P, et al: Propranolol for severe infantile hemangiomas:
Follow-up report. Pediatrics. 124:e423–e431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ou JM, Ye B, Qiu MK, Dai YX, Dong Q, Shen
J, Dong P, Wang XF, Liu YB, Quan ZW, et al: Knockdown of Livin
inhibits growth and invasion of gastric cancer cells through
blockade of the MAPK pathway in vitro and in vivo.
Int J Oncol. 44:276–284. 2014.PubMed/NCBI
|
|
6
|
Farah IO, Begum RA and Ishaque AB:
Differential protection and transactivation of P53, P21, Bcl2,
PCNA, cyclin G, and MDM2 genes in rat liver and the HepG2 cell line
upon exposure to pifithrin. Biomed Sci Instrum. 43:116–121.
2007.PubMed/NCBI
|
|
7
|
Razon MJ, Kräling BM, Mulliken JB and
Bischoff J: Increased apoptosis coincides with onset of involution
in infantile hemangioma. Microcirculation. 5:189–195. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ou JM, Yu ZY, Qiu MK, Dai YX, Dong Q, Shen
J, Wang XF, Liu YB, Quan ZW and Fei ZW: Knockdown of VEGFR2
inhibits proliferation and induces apoptosis in hemangioma-derived
endothelial cells. Eur J Histochem. 58:22632014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ou JM, Qui MK, Dai YX, Dong Q, Shen J,
Dong P, Wang XF, Liu YB and Fei ZW: Combined blockade of AKT/mTOR
pathway inhibits growth of human hemangioma via downregulation of
proliferating cell nuclear antigen. Int J Immunopathol Pharmacol.
25:945–953. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ou JM, Lian WS, Qiu MK, Dai YX, Dong Q,
Shen J, Dong P, Wang XF, Liu YB, Quan ZW, et al: Knockdown of IGF2R
suppresses proliferation and induces apoptosis in hemangioma cells
in vitro and in vivo. Int J Oncol. 45:1241–1249.
2014.PubMed/NCBI
|
|
11
|
Fridman JS and Lowe SW: Control of
apoptosis by p53. Oncogene. 22:9030–9040. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murphy PJ, Galigniana MD, Morishima Y,
Harrell JM, Kwok RP, Ljungman M and Pratt WB: Pifithrin-alpha
inhibits p53 signaling after interaction of the tumor suppressor
protein with hsp90 and its nuclear translocation. J Biol Chem.
279:30195–30201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uehata M, Ishizaki T, Satoh H, Ono T,
Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M,
et al: Calcium sensitization of smooth muscle mediated by a
Rho-associated protein kinase in hypertension. Nature. 389:990–994.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahara A, Sugiyama A, Satoh Y, Yoneyama
M and Hashimoto K: Cardiovascular effects of Y-27632, a selective
Rho-associated kinase inhibitor, assessed in the
halothane-anesthetized canine model. Eur J Pharmacol. 460:51–57.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Han S, Wang X, Han F, Zhu X, Zheng
Z, Wang H, Zhou Q, Wang Y, Su L, et al: Rho kinase inhibitor
Y-27632 promotes the differentiation of human bone marrow
mesenchymal stem cells into keratinocyte-like cells in xeno-free
conditioned medium. Stem Cell Res Ther. 6:172015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rath N and Olson MF: Rho-associated
kinases in tumorigenesis: Re-considering ROCK inhibition for cancer
therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morgan-Fisher M, Wewer UM and Yoneda A:
Regulation of ROCK activity in cancer. J Histochem Cytochem.
61:185–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kordek R, Biernat W, Alwasiak J and
Liberski PP: Proliferating cell nuclear antigen (PCNA) and Ki-67
immunopositivity in human astrocytic tumours. Acta Neurochir
(Wien). 138:509–512; discussion 513. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Li X, Parra M, Verdin E,
Bassel-Duby R and Olson EN: Control of endothelial cell
proliferation and migration by VEGF signaling to histone
deacetylase 7. Proc Natl Acad Sci USA. 105:7738–7743. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun H, Breslin JW, Zhu J, Yuan SY and Wu
MH: Rho and ROCK signaling in VEGF-induced microvascular
endothelial hyperpermeability. Microcirculation. 13:237–247. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kroll J, Epting D, Kern K, Dietz CT, Feng
Y, Hammes HP, Wieland T and Augustin HG: Inhibition of
Rho-dependent kinases ROCK I/II activates VEGF-driven retinal
neovascularization and sprouting angiogenesis. Am J Physiol Heart
Circ Physiol. 296:H893–H899. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu YF, Zhang Y, Shen N, Zhang RY and Lu
XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric
carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takeba Y, Matsumoto N, Watanabe M,
Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura
T and Otsubo T: The Rho kinase inhibitor fasudil is involved in
p53-mediated apoptosis in human hepatocellular carcinoma cells.
Cancer Chemother Pharmacol. 69:1545–1555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghahremani Farhang M, Radaelli E, Haigh K,
Bartunkova S, Haenebalcke L, Marine JC, Goossens S and Haigh JJ:
Loss of autocrine endothelial-derived VEGF significantly reduces
hemangiosarcoma development in conditional p53-deficient mice. Cell
Cycle. 13:1501–1507. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ghahremani Farhang M, Goossens S and Haigh
JJ: The p53 family and VEGF regulation: ‘It's complicated’. Cell
Cycle. 12:1331–1332. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu
Y, Sun J, Cai J, Zhu H and Li Q: Norcantharidin inhibits tumor
angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer
Sci. 104:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murai A, Asa Abou S, Kodama A, Sakai H,
Hirata A and Yanai T: Immunohistochemical analysis of the
Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and
haemangiosarcomas. J Comp Pathol. 147:430–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji Y, Chen S, Li K, Xiao X, Xu T and Zheng
S: Upregulated autocrine vascular endothelial growth factor
(VEGF)/VEGF receptor-2 loop prevents apoptosis in
haemangioma-derived endothelial cells. Br J Dermatol. 170:78–86.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu Y, Zhang Q, Kang C, Zhang K, Zhang J,
Pu P, Wang G and Wang T: Inhibitory effects of adenovirus mediated
COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells
in vitro and in vivo. Int J Oncol. 35:583–591.
2009.PubMed/NCBI
|
|
32
|
Ma X and Bai Y: IGF-1 activates the
P13K/AKT signaling pathway via upregulation of secretory clusterin.
Mol Med Rep. 6:1433–1437. 2012.PubMed/NCBI
|
|
33
|
Jahn SC, Law ME, Corsino PE, Davis BJ,
Harrison JK and Law BK: Signaling mechanisms that suppress the
cytostatic actions of rapamycin. PLoS One. 9:e999272014. View Article : Google Scholar : PubMed/NCBI
|
